ABCG1 and coronary artery disorder: Consistent with the observation in the case–control study, four of the eight CpG sites in the ABCG1 amplicon exhibited significantly reduced methylation level in CHD patients compared to the control group (ABCG1_CpG_2, ABCG1_CpG_3/cg27243685, ABCG1_CpG_4, and ABCG1_CpG_8, ORs per −10% methylation ranging from 1.33 to 2.49, p < 0.024, FDR-adjusted p value < 0.038 for all by logistic regression model B, Table 3).